Marker Therapeutics Q2 2025 Earnings Report

Marker Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.55
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Marker Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.72 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Marker Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/13/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, August 14, 2025
• Conference Call Time: 4:00PM ET

Marker Therapeutics (NASDAQ:MRKR) (NASDAQ: MRKR) is a clinical‐stage biotechnology company specializing in the development of personalized T cell immunotherapies for the treatment of cancer. The company’s proprietary CLS100 T cell platform enables the isolation, expansion and activation of tumor‐specific T cells from patient blood samples. By capturing naturally occurring T cell clones that recognize cancer antigens, Marker Therapeutics seeks to create off‐the‐shelf and individualized cell therapy candidates designed to elicit durable antitumor responses while minimizing off‐target effects.

The company’s lead programs include MT-101 for acute myeloid leukemia and myelodysplastic syndromes, MT-202 targeting HPV16-positive tumors, and MT-103 addressing solid tumor indications such as non–small cell lung and head and neck cancers. Marker Therapeutics conducts clinical trials in the United States, collaborating with leading academic centers and contract research organizations. In parallel, the company maintains a robust preclinical pipeline to expand its antigen library and explore combination regimens with checkpoint inhibitors and other immunomodulatory agents.

Founded in 2015 and headquartered in Houston, Texas, Marker Therapeutics has assembled a multidisciplinary team of scientists, clinicians and manufacturing specialists. The organization operates state‐of‐the‐art GMP manufacturing facilities and works in strategic partnerships to enhance its cell processing capabilities. Marker’s translational research efforts draw on expertise in immunology, molecular biology and bioinformatics to refine its T cell engineering processes and accelerate the progression of candidates from the laboratory to the clinic.

Under the leadership of Chief Executive Officer Dr. Sam Dharmapuri and Chief Scientific Officer Dr. Sonia Das Gupta, Marker Therapeutics emphasizes a patient-centric approach and rigorous quality standards. The company is governed by a board of directors with extensive experience in oncology drug development and biotech commercialization. As Marker advances its immunotherapy platform, it continues to engage with regulatory authorities and industry collaborators to broaden the reach of its personalized cancer therapies, with the goal of delivering transformative treatment options to patients worldwide.